FDA 483 - Modavar Pharmaceuticals - November 15, 2024

An FDA inspection of Modavar Pharmaceuticals, LLC in Frederick, MD, revealed a significant deviation from established protocols. The firm failed to implement blinding procedures for analysts during IVRT studies, as required by their own Blinding Protocol. This indicates a lapse in adherence to internal study conduct procedures.